Rare disease growth and Alimera deal draw fresh attention to ANI Pharmaceuticals

ANI Pharmaceuticals (ANIP) is back on investor radar after strong growth in its rare disease business, led by Cortrophin Gel, and the completed acquisition of Alimera Sciences, which expanded the company’s ophthalmology product portfolio.

The recent attention around Cortrophin Gel and the Alimera deal comes as ANI’s share price, now at US$74.82, shows softer short term momentum with a 30 day share price return of 5.17% and a 90 day share price return of 9.69%. At the same time, long term total shareholder returns of 16.27% over one year and almost 2x over three years point to a much stronger multi year story.

If rare disease growth has you thinking about where else the market might be underappreciating future potential, it could be worth scanning 35 healthcare AI stocks

With shares giving up some ground over the past quarter despite solid rare disease and earnings growth, plus a reported intrinsic value gap and a price target above the current level, the key question is whether ANIP still offers upside or if the market has already priced in its next chapter.

Most Popular Narrative: 32.3% Undervalued

ANI Pharmaceuticals' most followed narrative places fair value at $110.50, well above the last close at $74.82. This frames a sizeable valuation gap for investors to assess.

There is significant, untapped growth potential for Cortrophin Gel across core and emerging indications (neurology, nephrology, rheumatology, pulmonology, ophthalmology, and gout), with patient populations far below prior peaks and epidemiological data suggesting the addressable market could be several times larger due to an aging population and the rising prevalence of chronic diseases supporting multiyear revenue expansion.

Want to see what kind of revenue build, margin profile, and future P/E this narrative leans on? The full story shows how those pieces connect.

Result: Fair Value of $110.50 (UNDERVALUED)

However, this hinges on Cortrophin Gel and key generics continuing to perform as modeled, as well as on Alimera and other acquired assets avoiding integration or reimbursement setbacks.

Another Angle: Earnings Multiple Sends a Different Signal

The fair value narrative leans heavily on discounted cash flows, yet the current P/E of 22.2x tells a more cautious story. It sits above the US Pharmaceuticals average of 17.6x and the fair ratio of 18.9x, which points to less of a clear discount and more valuation risk if expectations reset.

Before leaning too much on one story, it is worth pressure testing what that richer P/E implies for future results and how comfortable you are with that gap versus peers and the fair ratio. See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

With mixed signals on value and expectations, it makes sense to look under the hood yourself and move quickly while views are still forming. You can start with the 4 key rewards and 3 important warning signs

Looking for more investment ideas?

If ANIP has you thinking bigger, now is a good moment to widen your watchlist and spot other opportunities before they attract broader attention.

• Target dependable cash generators with solid balance sheets by scanning companies in the solid balance sheet and fundamentals stocks screener (40 results)
• Hunt for quality at a discount by reviewing companies highlighted in the 49 high quality undervalued stocks
• Prioritize resilience and focus on stability by checking out the 72 resilient stocks with low risk scores

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.